|
[1]REGIMBEAU JM,KINMANESH R,FARGES O,et al.Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma[J].Sugery,2002,131(3):311-317.
|
|
[2]PANG RW,JOHN JW,JOHNSON PJ,et al.Biology of hepatocellular carcinoma[J].Ann Surg Oncol,2008,15(4):962-971.
|
|
[3]LEE KT,WANG SN,SU RW,et al.Is wider surgical margin justified for better clinical outcomes in patients with resectable hepatocellular carcinoma[J].J Formos Med Assoc,2012,111(3):160-170.
|
|
[4]LI HY,WEI YG,YAN LN,et al.Salvage liver transplantation in the treatment of hepatocellular carcinoma:a meta-analysis[J].World J Gastroenterol,2012,18(19):2415-2422.
|
|
[5]KULIK LM,FISHER RA,RODRIGO DR,et al.Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma:results of the A2ALL cohort[J].Am J Transplant,2012,12(11):2997-3007.
|
|
[6]BHANGUI P,VIBERT E,MAJNO P,et al.Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma:living versus deceased donor transplantation[J].Hepatology,2011,53(5):1570-1579.
|
|
[7]KIM YS,RHIM H,LIM HK,et al.Intraoperative radiofrequency ablation for hepatocellular carcinoma:long-term results in a large series[J].Ann Surg Oncol,2008,15(7):1862-1870.
|
|
[8] PENG ZW,LIN XJ,ZHANG YJ,et al.Radiofrequency ablation versus hepatic for the treatment of hepatocellular carcinomas 2 cm or smaller:a retrospective comparative study[J].Radiology,2012,262(3):1022-1033.
|
|
[9]ROSSI S,RAVETT V,ROSA L,et al.Repeated radiofrequency ablation for managenemt of patients with cirrhosis with small hepatocellular carcinoma:a long-term cohort study[J].Hepatology,2011,53(1):136-147.
|
|
[10]LLOVET JM,BRUIX J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.
|
|
[11]JIANG M,MA HB,YANG RM.Efficacy of transarterial chemoembolization in treatment of primary liver cancer:an analysis of 200cases[J].Curr Physician,2012,18(27):70-71.(in Chinese)蒋明,马华兵,杨瑞梅.肝动脉化疗栓塞治疗原发性肝癌200例分析[J].当代医学,2012,18(27):70-71.
|
|
[12]FAN WZ,WENG HW,YAO XH,et al.A meta analysis of combination of transcathether arterial chemoembolization and iodine-125seads for treatnaent of hepatocelluar carcinoma[J/CD].J Dig Oncol:Electronic Version,2013,5(2):114-118.(in Chinese)范文哲,翁慧雯,姚学华,等.经肝动脉栓塞化疗联合125I粒子治疗肝细胞癌的Meta分析[J/CD].消化肿瘤杂志:电子版,2013,5(2):114-118.
|
|
[13]WANG SS,ZENG QL,CHEN Y,et al.Efficacy of microcatheter superselective catheterization in interventional treatment of small hepatocellular carcinoma[J].The J Pract Med,2012,28(11):1850-1852.(in Chinese)汪盛参,曾庆乐,陈勇,等.微导管超选择插管介入治疗小肝癌的疗效[J].实用医学杂志,2012,28(11):1850-1852.
|
|
[14]DAWSON LA,NORMOLLE D,BALTER JM,et al.Analysis of radiation-induced liver disease using the Lyman NTCP model[J].Int J Radiat Oncol Biol Phys,2002,53(4):810-821.
|
|
[15]HUANG G,LAI EC,LAN WY,et al.Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV–DNA levels[J].Ann Surg,2013,257(3):490-505.
|
|
[16]NOMOTO S,KANDA M,OKAMURA Y,et al.Epidermal growth factor-containing fibulin-like extracellular matrix protein 1,EFEMPl,a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis[J].Ann Surg Oncol,2010,17(3):923-932.
|
|
[17]GU H,LI C.Research progress in magnetic nanoparticles for magnetic resonance imaging and targeted therapy of hepatocellular carcinoma[J].J Clin Hepatol,2013,29(10):740-743.(in Chinese)顾晗,李澄.磁性纳米粒子在肝细胞癌磁共振成像及靶向治疗方面的研究进展[J].临床肝胆病杂志,2013,29(10):740-743.
|
|
[18] LLOVET JM,RICCI S,MAZZAFERRO V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
|
|
[19]CHUNG YH,HAN G,YOON JH,et al.Interim analysis of START:Study in Asia of the combination of TACE(transcatheter arterial chemoembolization)with sorafenib in patients with hepatocellular carcinoma trial[J].Int J Cancer,2013,132(10):2448-2458.
|
|
[20]ZHU AX.Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012:current status and future perspectives[J].Semin Oncol,2012,39(4):493-502.
|
|
[21]ZHANG Y,ZHANG MJ,JIA ZS.Research advances in cellular immunotherapy for primary hepatocellular carcinoma[J].J Clin Hepatol,2014,30(9):860-864.(in Chinese)张野,张明杰,贾战生.肝细胞癌细胞免疫治疗的研究进展[J].临床肝胆病杂志,2014,30(9):860-864.
|
|
[22]ZHAO JF,WANG JN,WU QS,et al.Effects of interferon-Aon recurrence and metastasis of hepatocellular carcinoma after tumor removement[J].J Clin Med Pract,2011,15(11):133-134.(in Chinese)赵家锋,王建南,吴青松,等.干扰素治疗原发性肝癌的临床疗效观察[J].实用临床医药杂志,2011,15(11):133-134.
|
|
[23]SHI SL,DONG XM,HU WN,et al.Clinical study of P53 gene therapy on primary hepatocarcinoma[J].Mod J Integr Tradit Chin West Med,2012,21(10):1036-1037.(in Chinese)史守良,董秀敏,胡万宁,等.P53基因治疗原发性肝癌的临床研究[J].现代中西医结合杂志,2012,21(10):1036-1037.
|
|
[24]COHEN GS,BLACK M.Multidisciplinary management of hepatocellular carcinoma:a model for therapy[J].J Multidiscip Healthc,2013,6:189-195.
|
DownLoad: